Medication info
LinaGent Duo Tablet 2.5/500mg

LinaGent Duo Tablet 2.5/500mg

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
Bright yellow, bilaterally convex oval film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902371 · Approved 2019.04.17 · Insurance code 649105910

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as those they had been taking as the initial dose. 3. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes

View approved original text

This medication is suitable for patients using both LinaGLIPTIN and Metformin and is used in conjunction with dietary and exercise therapy to assist blood sugar control in type 2 diabetes patients. It can help improve blood glucose management more effectively.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should take the same doses of linagliptin and metformin as those they had been taking as the initial dose. 3. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin.

Precautions

This medication may cause a very rare but serious side effect called lactic acidosis, thus it should not be used in patients with impaired renal function or liver function problems. Patients allergic to this drug’s main components, as well as those with type 1 diabetes or specific types of diabetes such as diabetic ketoacidosis, should also not receive it. Additionally, patients with severe renal impairment, acute infections, heart failure, liver function disorders, acute alcohol intoxication, pregnant women, or nursing mothers should not use this medication. This drug poses a risk of hypoglycemia; thus, it is important to closely monitor blood sugar levels when used with insulin or sulfonylureas, and dosage adjustments may be necessary. Patients with impaired renal function should regularly check renal function before and during treatment, and discontinue medication if their condition worsens. Patients with poor heart function should also use this medication cautiously; rare side effects such as acute pancreatitis or bullous pemphigoid may occur, so consult a physician immediately if any abnormal symptoms appear. This medication may reduce vitamin B12 levels; therefore, regular vitamin B12 tests should be conducted during long-term use. Before and after the administration of iodinated contrast agents used in radiological examinations, this medication should be temporarily discontinued, and it should also be paused for a certain period before and after surgery. Women who are pregnant or planning to become pregnant are advised not to use this medication, and nursing mothers should also avoid it. This medication is not recommended for children under 10 years of age, as its safety and efficacy have not been established. Elderly patients may have reduced renal function; thus, dosage should be adjusted and renal function should be monitored periodically. The effects of this medication on driving or operating machinery are not known; however, hypoglycemia symptoms should be taken into account. Overdose may cause serious side effects such as lactic acidosis; thus, immediate medical treatment should be sought, and dialysis may be needed. Store this medication in a place where it is not exposed to moisture and out of reach of children, and it is advisable not to transfer it to another container.

Side effects

  • Lactic acidosis
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficiency of Vitamin B12
  • hypoglycemia
  • taste disturbances
  • cough
  • decreased appetite
Show 108 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • vesicular dermatitis
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • constipation
  • epigastric pain
  • gastroenteritis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorders
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • stomach cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • pneumonia
  • hypertension
  • pruritus
  • insomnia
  • depression
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • viral upper respiratory infection
  • periodontitis
  • influenza
  • dyspepsia
  • stomatitis
  • increased blood creatinine
  • facial edema
  • back pain
  • osteoarthritis
  • limb pain
  • headache
  • drowsiness
  • palpitations
  • nosebleed
  • oropharyngeal pain
  • voice disorders
  • epistaxis
  • hearing loss
  • erectile dysfunction
  • thyroid gland enlargement
  • confusion
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air and moisture. In addition, to maintain the efficacy of the drug, it should be stored at room temperature between 1 degree and 30 degrees.

Appearance and packaging

Appearance

Bright yellow, bilaterally convex oval film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.